Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 10 mg Psilocybin Clear all

Conditions: PTSD
Interventions: psilocybin, Supportive Therapy, Prolonged Exposure Therapy; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions: Psilocybin; Drug
Lead sponsor: Robin Carhart-Harris, PhD, MA; Other
Eligibility: 21 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions: Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cluster Headache
Interventions: 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Aging
Interventions: Psilocybin; Drug
Lead sponsor: University of California, Berkeley; Other
Eligibility: 60 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Post-Traumatic Headache
Interventions: Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alcohol Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stuttering
Interventions: Psilocybin, Speech therapy; Drug · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Healthy
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Well-Being, Psychological, Psychedelic Experiences
Interventions: Psilocybin, Saline Placebo, Clonidine; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Amblyopia
Interventions: Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin; Behavioral · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions: Psilocybin (drug), Dextromethorphan (DXM); Drug
Lead sponsor: Jennifer Mitchell; Other
Eligibility: 50 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pain Management, Postoperative Pain
Interventions: Psilocybin (Usona Institute), Postoperative analgesia; Drug
Lead sponsor: Trent Emerick; Other
Eligibility: 25 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 62
States / cities: Gilbert, Arizona • Bellflower, California • Encino, California + 50 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg; Drug
Lead sponsor: Francisco A Moreno; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy, Psychedelic Experiences, Sleep
Interventions: Psilocybin, Clonidine, Saline; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: La Jolla, California • Jacksonville, Florida • Rockville, Maryland + 2 more

Conditions: Nicotine Dependence
Interventions: Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Interventions: COMP360 psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 12 more

Conditions: Depressive Disorder, Major
Interventions: Psilocybin, Niacin, Set and Setting (SaS) Protocol; Drug · Other
Lead sponsor: Usona Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Santa Monica, California • New Haven, Connecticut + 8 more

Search by objective public record fields.

Psilocybin-Assisted Therapy

Study of Psilocybin Under Anesthesia Controlled by EEG

Neural and Physiological Correlates of Psychedelic Sub-states

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

Psilocybin for the Treatment of Cluster Headache

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Effects of Psilocybin in Concussion Headache

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

Psilocybin for Major Depressive Disorder (MDD)

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Psilocybin for Amblyopia - Targeting Critical Periods in Humans

Mechanistic Studies of Psilocybin in Headache Disorders

A Study of Psychedelics in Healthy Older Adults With Low Well-being

Psilocybin After Trauma Surgery for Pain

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Consciousness, Psilocybin, and Well-Being

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

A Study of Psilocybin for Major Depressive Disorder (MDD)